CLOUDBREAK-B(02592),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02592 CLOUDBREAK-B

Closed 01-12 16:08:30

3.050

+0.120

+4.10%

High3.190	Low2.940	Vol2.10M
Open2.990	D1 Closing2.930	Amplitude8.53%
Mkt Cap2.59B	Tradable Cap2.59B	Total Shares850.00M
T/O6.49M	T/O Rate0.25%	Tradable Shares850.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":3.05,"timestamp":1768205310003,"preClose":2.93,"halted":0,"volume":2103000,"delay":0,"floatShares":850000000,"shares":850000000,"eps":-0.208525,"marketStatus":"Closed","change":0.12,"latestTime":"01-12 16:08:30","open":2.99,"high":3.19,"low":2.94,"amount":6487120,"amplitude":0.085324,"askPrice":3.06,"askSize":80500,"bidPrice":3.05,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":-0.386,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":2.93,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.197833,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"1157588045","title":"CLOUDBREAK-B (02592): Court Orders Judicial Preservation of CLOUDBREAK Guangzhou's Bank Account at ICBC Until November 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1157588045","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157588045?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:58","pubTimestamp":1767797915,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on January 6, 2026, CLOUDBREAK Biopharmaceutical Technology (Guangzhou) Co., Ltd., an indirect wholly-owned subsidiary, received a notice issued by the Guangzhou...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161121","02592","BK1161"],"gpt_icon":0},{"id":"2601046658","title":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601046658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601046658?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:57","pubTimestamp":1767797842,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 DecemberJan 7  - Cloudbreak Pharma Inc 2592.HK:UNIT RECEIVES COURT NOTICE DATED 24 DECEMBERCOURT ORDERS PRESERVATION OF CLOUDBREAK GUANGZHOU'S RMB2.55 MILLION ACCOUNT TILL NOV 30, 2026Further company coverage: 2592.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601280170","title":"Court Freezes Cloudbreak Pharma Subsidiary’s Bank Account in Legal Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2601280170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601280170?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797265,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Subsidiary Cloudbreak Guangzhou Faces Legal Proceedings and Asset Preservation Order. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4qWTwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601801792","title":"Cloudbreak Pharma Inc - Court Orders Preservation of Cloudbreak Guangzhou's RMB2.55 Mln Account Till Nov 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601801792?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797255,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601962538","title":"Cloudbreak Pharma's US Unit Submits Application for Juvenile Myopia Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601962538","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601962538?lang=en_us&edition=fundamental","pubTime":"2026-01-06 18:50","pubTimestamp":1767696614,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma's  US unit, ADS Therapeutics, submitted an investigational new drug application for CBT-009 to China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The clinical-stage ophthalmology biotechnology company developed the drug for the treatment of juvenile myopia in children and adolescents aged 5 to 19.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1120737026","title":"CLOUDBREAK-B (02592) Successfully Submits CBT-009 New Drug Clinical Trial Application to Drug Review Center","url":"https://stock-news.laohu8.com/highlight/detail?id=1120737026","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120737026?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:47","pubTimestamp":1767689220,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, United States, has successfully submitted a new drug clinical trial...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","02592","BK1161","BK4090"],"gpt_icon":0},{"id":"2601686779","title":"Cloudbreak Pharma Inc -  Unit Submitted Ind Application for Cbt-009 to Center for Drug Evaluation to Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601686779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601686779?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:39","pubTimestamp":1767688761,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y616N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601867179","title":"Cloudbreak Pharma Submits IND Application for CBT-009 to China CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=2601867179","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601867179?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:38","pubTimestamp":1767688727,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully submitted an Investigational New Drug  application for CBT-009 to the Center for Drug Evaluation  of the National Medical Products Administration  in China. This milestone marks a significant step in the clinical development process for CBT-009, paving the way for potential Phase III clinical trials in the Chinese market. The company will continue to monitor the evaluation progress and update shareholders and investors as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL7wb7SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601009050","title":"Cloudbreak Pharma's Cornerstone Investor to Extend IPO Share Lock-Up; Shares Plunge 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601009050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601009050?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:30","pubTimestamp":1767601825,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma  said its cornerstone investor, Wealth Strategy, will extend the lock-up undertakings for the shares it subscribed to during the firm's IPO to July 2, according to a Jan. 2 Hong Kong bourse filing.Shares of the clinical-stage ophthalmology biotechnology company were down nearly 16% in Monday afternoon trading.The lock-up period was supposed to expire Jan. 3, the filing said.As of Monday, Wealth Strategy holds over 15.5 million shares in the firm, or a 1.84% holding.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","MST","09399","MSII","MSTU","MTYY","APED","MSDD","02592","MSTP","MSTZ","BK4585","BK4595","07799","07399","SMST","BK4023","MSOO","MSTX","3LMI.UK","BK4600","IMST","BK4516","BK4596","MSST","MSTY","WNTR","3SMI.UK","SMI3.UK","MSTK","09799","LMI3.UK","MSTW","BK4588","MSTY.UK"],"gpt_icon":0},{"id":"1101251542","title":"Hong Kong Stocks Movement | CLOUDBREAK-B (02592) Plunges Over 18%, Hits New Listing Low as Lock-up Expires Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1101251542","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101251542?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:56","pubTimestamp":1767578203,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) plummeted more than 18%, hitting a new low since its listing at HKD 3.69 during the trading session. As of the time of writing, the stock was down 18.18%, trading at HKD 3.69,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1113691420","title":"Cloudbreak-B (02592) Issues 1.785 Million Shares Under 2023 Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1113691420","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113691420?lang=en_us&edition=fundamental","pubTime":"2026-01-04 18:54","pubTimestamp":1767524050,"startTime":"0","endTime":"0","summary":"Cloudbreak-B (02592) announced that on January 3, 2026, it allotted and issued 1.785 million shares pursuant to its 2023 equity incentive plan.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2600090326","title":"Following recent decline, Cloudbreak Pharma Inc.'s (HKG:2592) top shareholder CEO Jinsong Ni sees holdings value drop by 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600090326","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600090326?lang=en_us&edition=fundamental","pubTime":"2026-01-03 08:17","pubTimestamp":1767399431,"startTime":"0","endTime":"0","summary":"Key Insights Cloudbreak Pharma's significant insider ownership suggests inherent interests in company's expansion The...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/following-recent-decline-cloudbreak-pharma-incs-hkg2592-top","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/following-recent-decline-cloudbreak-pharma-incs-hkg2592-top","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1114669997","title":"CLOUDBREAK-B (02592): Cornerstone Investor Fucé Holdings Voluntarily Extends Lock-up Period","url":"https://stock-news.laohu8.com/highlight/detail?id=1114669997","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114669997?lang=en_us&edition=fundamental","pubTime":"2026-01-02 12:18","pubTimestamp":1767327496,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on January 1, 2026, the company received a voluntary undertaking letter from one of its cornerstone investors, Fucé Holdings Limited. Pursuant to this, Fucé...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1120732671","title":"Hong Kong Stock Movement | CLOUDBREAK-B (02592) Surges Over 9% Intraday as Largest Single Shareholder Vows to Extend Lock-up Period by Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1120732671","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120732671?lang=en_us&edition=fundamental","pubTime":"2025-12-31 10:36","pubTimestamp":1767148580,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million. On the news front,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1168499401","title":"CLOUDBREAK-B (02592) Secures Lock-up Extension from Major Shareholder Water Lily","url":"https://stock-news.laohu8.com/highlight/detail?id=1168499401","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168499401?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:50","pubTimestamp":1767005430,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on December 29, 2025, the company received a voluntary undertaking letter from one of its single largest shareholders, Water Lily Consultants Inc. Water Lily has...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1142110567","title":"HK Stock Movement | CLOUDBREAK-B (02592) Plunged Nearly 15% as CBT-199 Ophthalmic Drug Candidate Files IND Application in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1142110567","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142110567?lang=en_us&edition=fundamental","pubTime":"2025-12-16 10:30","pubTimestamp":1765852217,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","CBT","BK4090","02592"],"gpt_icon":0},{"id":"2591643029","title":"Cloudbreak Pharma Unit Submits Application to US FDA for Presbyopia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643029","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643029?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:56","pubTimestamp":1765799768,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma  unit ADS Therapeutics submitted an investigational new drug application for CBT-199 to the U.S. Food and Drug Administration , a Monday Hong Kong bourse filing said.CBT-199 is a novel topical ophthalmic emulsion indicated for the treatment of presbyopia, a gradual loss of the eyes' ability to focus on nearby objects.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2591661031","title":"BRIEF-Cloudbreak Pharma Says ADS Therapeutics Submits IND Application To FDA For CBT-199","url":"https://stock-news.laohu8.com/highlight/detail?id=2591661031","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591661031?lang=en_us&edition=fundamental","pubTime":"2025-12-15 18:24","pubTimestamp":1765794248,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Says ADS Therapeutics Submits IND Application To FDA For CBT-199Dec 15 (Reuters) - Cloudbreak Pharma Inc 2592.HK:ADS THERAPEUTICS SUBMITS IND APPLICATION TO FDA FOR CBT-199Further company coverage: 2592.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL08Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1197653605","title":"CLOUDBREAK-B (02592) Submits IND Application for CBT-199 to U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1197653605","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197653605?lang=en_us&edition=fundamental","pubTime":"2025-12-15 17:18","pubTimestamp":1765790301,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on December 15, 2025, its wholly-owned subsidiary, ADS Therapeutics LLC, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4090","02592","CBT","BK1161"],"gpt_icon":0},{"id":"2591614388","title":"Cloudbreak Pharma Inc - Ads Therapeutics Submits Ind Application to FDA for Cbt-199","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591614388?lang=en_us&edition=fundamental","pubTime":"2025-12-15 17:13","pubTimestamp":1765789987,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL08Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":-0.3503},{"period":"1month","weight":-0.6356},{"period":"3month","weight":-0.2854},{"period":"6month","weight":-0.4878},{"period":"1year","weight":-0.7099},{"period":"ytd","weight":-0.4365}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. The Company is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The Company has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.","exchange":"SEHK","name":"CLOUDBREAK-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLOUDBREAK-B(02592),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLOUDBREAK-B(02592) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLOUDBREAK-B,02592,CLOUDBREAK-B股票,CLOUDBREAK-B股票老虎,CLOUDBREAK-B股票老虎国际,CLOUDBREAK-B行情,CLOUDBREAK-B股票行情,CLOUDBREAK-B股价,CLOUDBREAK-B股市,CLOUDBREAK-B股票价格,CLOUDBREAK-B股票交易,CLOUDBREAK-B股票购买,CLOUDBREAK-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLOUDBREAK-B(02592),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLOUDBREAK-B(02592) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}